FREE SHIPPING over $40
OVER 10000 FIVE-STAR REVIEWS
5% OFF ALL SUBSCRIPTIONS
100% HAPPINESS GUARANTEE
Analyze Diet
0
Drug testing and analysis2021; 14(2); 233-251; doi: 10.1002/dta.3172

Comprehensive metabolic study of IOX4 in equine urine and plasma using liquid chromatography/electrospray ionization Q Exactive high-resolution mass spectrometer for the purpose of doping control.

Abstract: IOX4 is a hypoxia-inducible factor prolyl hydroxylase (HIF-PHD) inhibitor, which was developed for the treatment of anemia by exerting hematopoietic effects. The administration of HIF-PHD inhibitors such as IOX4 to horses is strictly prohibited by the International Federation of Horseracing Authorities and the Fédération Équestre Internationale. To the best of our knowledge, this is the first comprehensive metabolic study of IOX4 in horse plasma and urine after a nasoesophageal administration of IOX4 (500 mg/day, 3 days). A total of four metabolites (three mono-hydroxylated IOX4 and one IOX4 glucuronide) were detected from the in vitro study using homogenized horse liver. As for the in vivo study, post-administration plasma and urine samples were comprehensively analyzed with liquid chromatography/electrospray ionization high-resolution mass spectrometry to identify potential metabolites and determine their corresponding detection times. A total of 10 metabolites (including IOX4 glucuronide, IOX4 glucoside, O-desbutyl IOX4, O-desbutyl IOX4 glucuronide, four mono-hydroxylated IOX4, N-oxidized IOX4, and N-oxidized IOX4 glucoside) were found in urine and three metabolites (glucuronide, glucoside, and O-desbutyl) in plasma. Thus, the respective quantification methods for the detection of free and conjugated IOX4 metabolites in urine and plasma with a biphase enzymatic hydrolysis were developed and applied to post-administration samples for the establishment of elimination profiles of IOX4. The detection times of total IOX4 in urine and plasma could be successfully prolonged to at least 312 h.
© 2021 John Wiley & Sons, Ltd.
Get Full Text
Publication Date: 2021-10-21 PubMed ID: 34612014DOI: 10.1002/dta.3172Google Scholar: Lookup
The Equine Research Bank provides access to a large database of publicly available scientific literature. Inclusion in the Research Bank does not imply endorsement of study methods or findings by Mad Barn.
LinkedInCopy
  • Journal Article

Summary

This research summary has been generated with artificial intelligence and may contain errors and omissions. Refer to the original study to confirm details provided. Submit correction.

The research article details a comprehensive metabolic study of IOX4, a substance used to treat anemia, which is prohibited for use in horses by major horse racing and equestrian authorities. Using a high-resolution mass spectrometer, the researchers investigated the metabolic effects of IOX4 in horse plasma and urine, uncovering a total of ten metabolites in urine and three in plasma.

Overview of Research

  • The researchers conducted a thorough analysis of the metabolic effects of IOX4 in the plasma and urine of horses. This study was deemed necessary because IOX4, despite its medical usage in treating anemia, is strongly forbidden in equine sports due to the potential for misuse in enhancing performance.
  • The researchers administered IOX4 to horses using a nasoesophageal method at a dose of 500mg/day for three consecutive days. The metabolites present after administration were then analysed both in vitro (in the lab) and in vivo (in the body).

Metabolite Analysis

  • Using a homogenized horse liver for the in vitro study, the researchers discovered a total of four metabolites of IOX4 (three mono-hydroxylated IOX4 and one IOX4 glucuronide).
  • The in vivo study involved a comprehensive analysis of post-administration plasma and urine samples, powered by liquid chromatography/electrospray ionization high-resolution mass spectrometry. The primary objective was to identify potential metabolites and establish the corresponding detection times for each.
  • In conclusion, ten metabolites (IOX4 glucuronide, IOX4 glucoside, O-desbutyl IOX4, O-desbutyl IOX4 glucuronide, four mono-hydroxylated IOX4, N-oxidized IOX4, and N-oxidized IOX4 glucoside) were found in urine samples, while three metabolites (glucuronide, glucoside, and O-desbutyl) were found in plasma samples post-administration of IOX4.

Detection and Quantification Method

  • A quantification method for the detection of free and conjugated IOX4 metabolites in urine and plasma was also developed through a procedure the researchers referred to as a “biphase enzymatic hydrolysis”.
  • This method was applied to samples after administration helping to create profiles for the elimination of IOX4 from the system.
  • As a result of this method, the detection times of total IOX4 in both urine and plasma samples were effectively stretched to at least 312 hours post-administration.

Cite This Article

APA
Ishii H, Shibuya M, So YM, Wong JKY, Ho ENM, Kusano K, Sone Y, Kamiya T, Wakuno A, Ito H, Miyata K, Yamada M, Leung GN. (2021). Comprehensive metabolic study of IOX4 in equine urine and plasma using liquid chromatography/electrospray ionization Q Exactive high-resolution mass spectrometer for the purpose of doping control. Drug Test Anal, 14(2), 233-251. https://doi.org/10.1002/dta.3172

Publication

Drug testing and analysis
ISSN: 1942-7611
NlmUniqueID: 101483449
Country: England
Language: English
Volume: 14
Issue: 2
Pages: 233-251

Researcher Affiliations

Ishii, Hideaki
  • Drug Analysis Department, Laboratory of Racing Chemistry, Utsunomiya, Tochigi, Japan.
  • Department of Pharmaceutical Sciences, Tohoku University Hospital, Sendai, Miyagi, Japan.
Shibuya, Mariko
  • Drug Analysis Department, Laboratory of Racing Chemistry, Utsunomiya, Tochigi, Japan.
So, Yat-Ming
  • Racing Laboratory, The Hong Kong Jockey Club, Sha Tin Racecourse, Sha Tin, N.T., Hong Kong.
Wong, Jenny K Y
  • Racing Laboratory, The Hong Kong Jockey Club, Sha Tin Racecourse, Sha Tin, N.T., Hong Kong.
Ho, Emmie N M
  • Racing Laboratory, The Hong Kong Jockey Club, Sha Tin Racecourse, Sha Tin, N.T., Hong Kong.
Kusano, Kanichi
  • Veterinarian Section, Equine Department, JRA, Minato, Tokyo, Japan.
Sone, Yu
  • Veterinarian Section, Equine Department, JRA, Minato, Tokyo, Japan.
Kamiya, Takahiro
  • Equine Veterinary Clinic, Horse Racing School, Japan Racing Association, Shiroi, Chiba, Japan.
Wakuno, Ai
  • Equine Veterinary Clinic, Horse Racing School, Japan Racing Association, Shiroi, Chiba, Japan.
Ito, Hideki
  • Equine Veterinary Clinic, Horse Racing School, Japan Racing Association, Shiroi, Chiba, Japan.
Miyata, Kenji
  • JRA Equestrian Park Utsunomiya Office, Utsunomiya, Tochigi, Japan.
Yamada, Masayuki
  • Drug Analysis Department, Laboratory of Racing Chemistry, Utsunomiya, Tochigi, Japan.
Leung, Gary Ngai-Wa
  • Drug Analysis Department, Laboratory of Racing Chemistry, Utsunomiya, Tochigi, Japan.

MeSH Terms

  • Animals
  • Chromatography, Liquid / methods
  • Doping in Sports / prevention & control
  • Glucuronides
  • Horses
  • Plasma
  • Spectrometry, Mass, Electrospray Ionization / methods

Grant Funding

  • Japan Racing Association

References

This article includes 39 references
  1. WIPO PCT. Oral antidiabetic agents. .
  2. European Patent Office. Substituted dihydropyrazolones for treating cardiovascular and haematological diseases. .
  3. Beck H, Jeske M, Thede K. Discovery of molidustat (BAY 85-3934): a small-molecule oral HIF-prolyl hydroxylase (HIF-PH) inhibitor for the treatment of renal anemia. ChemMedChem 2018;13(10):988-1003.
    doi: 10.1002/cmdc.201700783google scholar: lookup
  4. Figg WD Jr, McDonough MA, Chowdhury R. Structural basis of prolyl hydroxylase domain inhibition by molidustat. ChemMedChem 2021;16(13):2082-2088.
    doi: 10.1002/cmdc.202100133google scholar: lookup
  5. Min JH, Yang H, Ivan M, Gertler F, Kaelin WG Jr, Pavletich NP. Structure of an HIF-1alpha-pVHL complex: hydroxyproline recognition in signaling. Science 2002;296(5574):1886-1889.
    doi: 10.1126/science.1073440google scholar: lookup
  6. Muchnik E, Kaplan J. HIF prolyl hydroxylase inhibitors for anemia. Expert Opin Investig Drugs 2011;20(5):645-656.
    doi: 10.1517/13543784.2011.566861google scholar: lookup
  7. Yan L, Colandrea VJ, Hale JJ. Prolyl hydroxylase domain-containing protein inhibitors as stabilizers of hypoxia-inducible factor: small molecule-based therapeutics for anemia. Expert Opin Ther Pat 2010;20(9):1219-1245.
    doi: 10.1517/13543776.2010.510836google scholar: lookup
  8. Bunn HF. New agents that stimulate erythropoiesis. Blood 2007;109(3):868-873.
    doi: 10.1182/blood-2006-08-019083google scholar: lookup
  9. Chan MC, Atasoylu O, Hodson E. Potent and selective triazole-based inhibitors of the hypoxia-inducible factor prolyl-hydroxylases with activity in the murine brain. PLoS One 2015;10(7):e0132004.
    doi: 10.1371/journal.pone.0132004google scholar: lookup
  10. Beuck S, Schänzer W, Thevis M. Hypoxia-inducible factor stabilizers and other small-molecule erythropoiesis-stimulating agents in current and preventive doping analysis. Drug Test Anal 2012;4(11):830-845.
    doi: 10.1002/dta.390google scholar: lookup
  11. Joharapurkar AA, Pandya VB, Patel VJ, Desai RC, Jain MR. Prolyl hydroxylase inhibitors: a breakthrough in the therapy of anemia associated with chronic diseases. J Med Chem 2018;61(16):6964-6982.
    doi: 10.1021/acs.jmedchem.7b01686google scholar: lookup
  12. Mazzarino M, Perretti I, Stacchini C, Comunità F, de la Torre X, Botrè F. UPLC-MS-based procedures to detect prolyl-hydroxylase inhibitors of HIF in urine. J Anal Toxicol 2021;45(2):184-194.
    doi: 10.1093/jat/bkaa055google scholar: lookup
  13. Hu CJ, Wang LY, Chodosh LA, Keith B, Simon MC. Differential roles of hypoxia-inducible factor 1alpha (HIF-1alpha) and HIF-2alpha in hypoxic gene regulation. Mol Cell Biol 2003;23(24):9361-9374.
    doi: 10.1128/mcb.23.24.9361-9374.2003google scholar: lookup
  14. Elvert G, Kappel A, Heidenreich R. Cooperative interaction of hypoxia-inducible factor-2alpha (HIF-2alpha) and Ets-1 in the transcriptional activation of vascular endothelial growth factor receptor-2 (Flk-1). J Biol Chem 2003;278(9):7520-7530.
    doi: 10.1074/jbc.m211298200google scholar: lookup
  15. Semenza GL. A compendium of proteins that interact with HIF-1α. Exp Cell Res 2017;356(2):128-135.
    doi: 10.1016/j.yexcr.2017.03.041google scholar: lookup
  16. Chan MC, Ilott NE, Schödel J. Tuning the transcriptional response to hypoxia by inhibiting hypoxia-inducible factor (HIF) prolyl and asparaginyl hydroxylases. J Biol Chem 2016;291(39):20661-20673.
    doi: 10.1074/jbc.m116.749291google scholar: lookup
  17. International Federation of Horseracing Authorities. International agreement on breeding, racing and wagering and appendixes (January 2021). .
  18. Fédération Équestre Internationale. 2021 Equine prohibited substances list. .
  19. World Anti-Doping Agency. 2021 List of prohibited substances and methods. .
  20. Thevis M, Schänzer W. Analytical approaches for the detection of emerging therapeutics and non-approved drugs in human doping controls. J Pharm Biomed Anal 2014;101:66-83.
    doi: 10.1016/j.jpba.2014.05.020google scholar: lookup
  21. Beuck S, Bornatsch W, Lagojda A, Schänzer W, Thevis M. Development of liquid chromatography-tandem mass spectrometry-based analytical assays for the determination of HIF stabilizers in preventive doping research. Drug Test Anal 2011;3(11-12):756-770.
    doi: 10.1002/dta.365google scholar: lookup
  22. Hansson A, Thevis M, Cox H. Investigation of the metabolites of the HIF stabilizer FG-4592 (roxadustat) in five different in vitro models and in a human doping control sample using high resolution mass spectrometry. J Pharm Biomed Anal 2017;134:228-236.
    doi: 10.1016/j.jpba.2016.11.041google scholar: lookup
  23. Thevis M, Milosovich S, Licea-Perez H, Knecht D, Cavalier T, Schänzer W. Mass spectrometric characterization of a prolyl hydroxylase inhibitor GSK1278863, its bishydroxylated metabolite, and its implementation into routine doping controls. Drug Test Anal 2016;8(8):858-863.
    doi: 10.1002/dta.1870google scholar: lookup
  24. Dib J, Mongongu C, Buisson C. Mass spectrometric characterization of the hypoxia-inducible factor (HIF) stabilizer drug candidate BAY 85-3934 (molidustat) and its glucuronidated metabolite BAY-348, and their implementation into routine doping controls. Drug Test Anal 2017;9(1):61-67.
    doi: 10.1002/dta.2011google scholar: lookup
  25. Buisson C, Marchand A, Bailloux I, Lahaussois A, Martin L, Molina A. Detection by LC-MS/MS of HIF stabilizer FG-4592 used as a new doping agent: investigation on a positive case. J Pharm Biomed Anal 2016;121:181-187.
    doi: 10.1016/j.jpba.2016.01.029google scholar: lookup
  26. Eichner D, Van Wagoner RM, Brenner M. lmplementation of the prolyl hydroxylase inhibitor Roxadustat (FG-4592) and its main metabolites into routine doping controls. Drug Test Anal 2017;9(11-12):1768-1778.
    doi: 10.1002/dta.2202google scholar: lookup
  27. Philip M, Mathew B, Karatt TK, Perwad Z, Subhahar MB, Karakka Kal AK. Metabolic studies of hypoxia-inducible factor stabilisers IOX2, IOX3 and IOX4 (in vitro) for doping control. Drug Test Anal 2021;13(4):794-816.
    doi: 10.1002/dta.3000google scholar: lookup
  28. Wong JK, Tang FP, Wan TS. In vitro metabolic studies using homogenized horse liver in place of horse liver microsomes. Drug Test Anal 2011;3(6):393-399.
    doi: 10.1002/dta.273google scholar: lookup
  29. Wong JK, Chan GH, Leung DK, Tang FP, Wan TS. Generation of phase II in vitro metabolites using homogenized horse liver. Drug Test Anal 2016;8(2):241-247.
    doi: 10.1002/dta.1850google scholar: lookup
  30. Akizawa T, Macdougall IC, Berns JS. Long-term efficacy and safety of molidustat for anemia in chronic kidney disease: DIALOGUE Extension Studies. Am J Nephrol 2019;49(4):271-280.
    doi: 10.1159/000499111google scholar: lookup
  31. Thevis M, Schmickler MH, Schänzert W. Mass spectrometric behavior of thiazide-based diuretics after electrospray ionization and collision-induced dissociation. Anal Chem 2002;74(15):3802-3808.
    doi: 10.1021/ac020020egoogle scholar: lookup
  32. Garcia P, Popot MA, Fournier F, Bonnaire Y, Tabet JC. Gas-phase behaviour of negative ions produced from thiazidic diuretics under electrospray conditions. J Mass Spectrom 2002;37(9):940-953.
    doi: 10.1002/jms.353google scholar: lookup
  33. Ishii H, Shibuya M, Leung GN. Metabolic study of GW1516 in equine urine using liquid chromatography/electrospray ionization Q-Exactive high-resolution mass spectrometry for doping control. Rapid Commun Mass Spectrom 2021;35(5):e9028.
    doi: 10.1002/rcm.9028google scholar: lookup
  34. Nakazawa T, Miyata K, Omura K, Iwanaga T, Nagata O. Metabolic profile of FYX-051 (4-(5-pyridin-4-yl-1h-1,2,4triazol-3-yl)pyridine-2-carbonitrile) in the rat, dog, monkey, and human: identification of N-glucuronides and N-glucosides. Drug Metab Dispos 2006;34(11):1880-1886.
    doi: 10.1124/dmd.106.011692google scholar: lookup
  35. Omura K, Nakazawa T, Sato T, Iwanaga T, Nagata O. Characterization of N-glucuronidation of 4-(5-pyridin-4-yl-1H-1,2,4triazol-3-yl) pyridine-2-carbonitrile (FYX-051): a new xanthine oxidoreductase inhibitor. Drug Metab Dispos 2007;35(12):2143-2148.
    doi: 10.1124/dmd.107.017251google scholar: lookup
  36. Chau N, Elliot DJ, Lewis BC. Morphine glucuronidation and glucosidation represent complementary metabolic pathways that are both catalyzed by UDP-glucuronosyltransferase 2B7: kinetic, inhibition, and molecular modeling studies. J Pharmacol Exp Ther 2014;349(1):126-137.
    doi: 10.1124/jpet.113.212258google scholar: lookup
  37. Mori T, Kishimoto S, Ijiro K, Kobayashi A, Okahata Y. A lipid-coated lipase as an efficient hydrolytic catalyst in the two-phase aqueous-organic system. Biotechnol Bioeng 2001;76(2):157-163.
    doi: 10.1002/bit.1155google scholar: lookup
  38. Lee SH, Park OJ, Uh HS. A chemoenzymatic approach to the synthesis of enantiomerically pure (S)-3-hydroxy-gamma-butyrolactone. Appl Microbiol Biotechnol 2008;79(3):355-362.
    doi: 10.1007/s00253-008-1439-9google scholar: lookup
  39. Momose T, Maruyama J, Iida T, Goto J, Nambara T. Comparative abilities and optimal conditions for beta-glycosidase enzymes to hydrolyse the glucuronide, glucoside, and N-acetylglucosaminide conjugates of bile acids. Biol Pharm Bull 1997;20(8):828-833.
    doi: 10.1248/bpb.20.828google scholar: lookup

Citations

This article has been cited 3 times.
  1. Ishii H, Shibuya M, Kusano K, Sone Y, Kamiya T, Wakuno A, Ito H, Miyata K, Sato F, Kuroda T, Yamada M, Leung GN. Generic approach for the discovery of drug metabolites in horses based on data-dependent acquisition by liquid chromatography high-resolution mass spectrometry and its applications to pharmacokinetic study of daprodustat. Anal Bioanal Chem 2022 Nov;414(28):8125-8142.
    doi: 10.1007/s00216-022-04347-2pubmed: 36181513google scholar: lookup
  2. Ishii H, Shibuya M, Kusano K, Sone Y, Kamiya T, Wakuno A, Ito H, Miyata K, Sato F, Kuroda T, Yamada M, Leung GN. Pharmacokinetic Study of Vadadustat and High-Resolution Mass Spectrometric Characterization of its Novel Metabolites in Equines for the Purpose of Doping Control. Curr Drug Metab 2022;23(10):850-865.
    doi: 10.2174/1389200223666220825093945pubmed: 36017833google scholar: lookup
  3. Ishii H, Shigematsu R, Takemoto S, Ishikawa Y, Mizobe F, Nomura M, Arima D, Kunii H, Yuasa R, Yamanaka T, Tanabe S, Nagata SI, Yamada M, Leung GN. Quantification of osilodrostat in horse urine using LC/ESI-HRMS to establish an elimination profile for doping control. Bioanalysis 2024;16(17-18):947-958.
    doi: 10.1080/17576180.2024.2385848pubmed: 39235065google scholar: lookup
Subscribe to our newsletter
Join 99,727 horse owners like you who receive our email updates on horse health and nutrition.